General Information of Drug (ID: DMSQZEP)

Drug Name
TAR-200 Drug Info
Indication
Disease Entry ICD 11 Status REF
Bladder cancer 2C94 Phase 1 [1]
Cross-matching ID
TTD Drug ID
DMSQZEP

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Discontinued Drug(s)
Drug(s) Targeting DNA synthesis (DNA synth)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Nelarabine DMB6VEG leukaemia 2A60-2B33 Approved [2]
Glufosfamide DMEFCTP Pancreatic cancer 2C10 Phase 3 [1]
acelarin DMY96O3 Biliary tract cancer 2C17 Phase 3 [1]
FF-10502-01 DMX5290 Lymphoma 2A80-2A86 Phase 1 [1]
CLOTURIN DMKFMYR Solid tumour/cancer 2A00-2F9Z Discontinued in Phase 2 [3]
EPD-clofarabine DM149HL Solid tumour/cancer 2A00-2F9Z Terminated [4]
⏷ Show the Full List of 6 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
DNA synthesis (DNA synth) TTUBNVO NOUNIPROTAC Inhibitor [1]

References

1 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2 Nelarabine. Drugs. 2008;68(4):439-47.
3 Inhibition of biosynthetic processes in P388 and Ehrlich ascites cells by cloturin. Drugs Exp Clin Res. 1988;14(9):575-80.
4 2004 approvals: the demise of the blockbuster. Nat Rev Drug Discov. 2005 Feb;4(2):93-4.